Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bevacizumab biosimilar - Biocad

Next Previous
Search
Drug Profile

Bevacizumab biosimilar - Biocad

Alternative Names: Avegra; BCD-021

Latest Information Update: 22 Jun 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocad
  • Developer Biocad; SPH-BIOCAD
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer

Most Recent Events

  • 27 Sep 2021 No development reported - Phase-III for Non-small cell lung cancer (Combination therapy, Late-stage disease) in Ukraine, India and Belarus (IV)
  • 30 Mar 2016 Biocad terminates phase I trial in Wet age-related macular degeneration in Russia (NCT02450981)
  • 30 Mar 2016 Biocad terminates the GALATIR trial in Wet age-related macular degeneration in Brazil and Russia (NCT02036723)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top